27256-91-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydrazinylpyridine hydrochloride is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs targeting specific disorders.
Used in Antimicrobial Applications:
4-Hydrazinylpyridine hydrochloride is used as a Hydrazonopyrrolidine derivative for preventing and/or treating disorders associated with Acinetobacter baumannii, a type of bacteria that can cause severe infections, particularly in hospitalized patients.

InChI:InChI=1/C5H7N3/c6-8-5-1-3-7-4-2-5/h1-4H,6H2,(H,7,8)

Upstream product

• 626-61-9 4-Chloropyridine 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 302-01-2 hydrazine 
• 20815-52-5 4-hydrazinopyridine hydrochloride 
• 7803-57-8 hydrazine hydrate 
• 74129-11-6 4-bromopyridine hydrobromide salt 
• 7647-01-0 hydrogenchloride 
• 26482-55-3 4-(nitroamino)pyridine 

Downstream Products

• 210173-41-4 N-(3-phenyl-propylidene)-N'-pyridin-4-yl-hydrazine 
• 210173-44-7 N-[3-(4-methoxy-phenyl)-propylidene]-N'-pyridin-4-yl-hydrazine 
• 210173-47-0 N-[3-(3-methoxy-phenyl)-propylidene]-N'-pyridin-4-yl-hydrazine 
• 210173-40-3 N-{3-[4-(tert-butyl-dimethyl-silanyloxy)-3-methoxy-phenyl]-propylidene}-N'-pyridin-4-yl-hydrazine 
• 626-61-9 4-Chloropyridine 
• 106898-37-7 5-amino-1-pyridin-4-yl-1H-pyrazole-4-carbonitrile 
• 20815-52-5 4-hydrazinopyridine dihydrochloride 
• 91396-98-4 4-(2-(2-hydroxybenzylidene)hydrazinyl)pyridine 
• 50356-97-3 4-(2-(2-methylbenzylidene)hydrazinyl)pyridine 
• 1215760-28-3 4-(2-(2-methoxybenzylidene)hydrazinyl)pyridine 
• 1370287-19-6 3-phenyl-N'-(pyridin-4-yl)propanehydrazide 
• 1443361-91-8 2-((4-(1-(pyridin-4-yl)-1H-pyrazol-5-yl)phenyl)ethynyl)quinoline 
• 1443362-68-2 4-(5-(4-((trimethylsilyl)ethynyl)phenyl)-1H-pyrazol-1-yl)pyridine 
• 1443362-69-3 4-(5-(4-ethynylphenyl)-1H-pyrazol-1-yl)pyridine 

Relevant academic research and scientific papers

Synthesis, CYP 450 evaluation, and docking simulation of novel 4-aminopyridine and coumarin derivatives

Four series of novel compounds based on 4-aminopyridine, glatiramer acetate, pyrone, and coumarin backbones were sufficiently synthesized and identified by spectroscopic methods. CYP enzyme inhibition assays of five predominate human P450 isozymes indicate that all compounds, except for 4-hydrazide pyridine 1c, seem to be less toxic than 4-aminopyridine. Further investigation of the compounds using molecular docking experiments revealed different, the same, or stronger binding modes for most of the synthesized compounds, with both polar and hydrophobic interactions with the 1WDA and 1J95 receptors compared to benzoyl l-arginine amide and 4-aminopyridine, respectively. These results introduce the synthesized compounds as K+ channel blockers that could be considered for in vivo CNS disease studies.

Synthesis and evaluation of pyridinium-hydrazone derivatives as potential antitumoral agents

The hydrazones of 4-hydrazinylpyridinium bearing alkylphenyl groups on pyridinium nitrogen were synthesized and evaluated for their cytotoxic activity against MCF-7, PC3, U2OS, and HEK293 cell lines by Wst1 cell proliferation assay. Cytotoxic activity results indicated that d derivatives having butylene chain; 4 and 5 series having naphthalene and anthracene ring systems showed high cytotoxic activity (IC50?=?3.27–8.54?μm) on cancer cells. 3d (4-(2-(4-hydroxybenzylidene)hydrazinyl)-1-(4-phenylbutyl)pyridinium bromide) was the most cytotoxic compound with IC50 value of 3.27?μm against MCF-7. The most active derivatives (1d, 2d, 3d, 4, and 5 series) were selected to investigate for the effects on autophagy by analyzing the expression of autophagy marker proteins. The conversion of LC3-I to its lipidated form LC3-II is essential for autophagy and related to autophagosomes. According to our results, all tested compounds except for 3d induced lipidated form LC3-II accumulation. Then, the effects of the compounds on p62 protein level were also analyzed by the immunoblotting as the autophagy inhibition results in accumulation of p62. Further molecular mechanistic studies including morphological analysis and live–death assays indicated that all tested compounds (1d, 2d, 3d, 4, and 5 series) are potent antitumoral molecules and all except for 3d have potential to inhibit autophagic flux.

The compound of the structural unit containing pyrazole

The invention discloses a compound containing a pyrazole structural unit. A structural general formula of the compound is shown as a formula I. Because that an electrophosphorescent material requires good film-forming performance and a high-efficiency phosphorescence material having short phosphorescence life, by aiming at enhancement of luminescence efficiency and luminescent device performance, the invention provides a series of electrophosphorescent materials of iridium or platinum complex having pyrazole group. The compound has excellent film forming ability and high luminescence efficiency, the raw material is easily available, the compound is simple to prepare, the total yield is high, the cost of phosphorescence material is greatly reduced, and the compound has important application value.

ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF

This invention relates to novel alkyne-bridged hetero-aromatics as described in the specification which are PDE10A inhibitors and useful for the treatment of neurological, psychiatric disorder, metabolic disorders, such as Schizophrenia, Parkinson's disea

UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER

Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.

IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS

The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently -O- or -NRN1-; RN1, if present, is independently -H or a substituent; RN2 is independently -H or a substituent; Y is independently -CH= or -N=; Q is independently -(CH2)j-M-(CH2)k- wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently -O-, -S-, -NH-, -NMe-, or -CH2-; each of RP1, RP2, RP3, and RP4 is independently -H or a substituent; and additionally RP1 and RP2 taken together may be -CH=CH-CH=CH-; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently -CH2-,-NRN-, -C(=X)-, or -S(=O)2-; exactly one linker moiety is -NRN-, or: exactly two linker moieties are -NRN-; exactly one linker moiety is -C(=X)-, and no linker moiety is -S(=O)2-; or: exactly one linker moiety is -S(=O)2-, and no linker moiety is -C(=X)-; no two adjacent linker moieties are -NRN-; X is independently =O or =S; each RN is independently -H or a substituent; A is independently: C6-14carboaryl, C5-14heteroaryl, C3-12carbocyclic, C3-12heterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF

A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.

Condensed pyrazole derivatives, process for producing the same and use thereof

Novel pharmaceutical compositions for inhibiting Th2-selective immune response and pharmaceutical compositions for inhibiting cyclooxygenase comprising condensed pyrazole derivatives represented by the general formula (I): or salts thereof.

Studies on synthetic approaches to 1H- and 2H-indazolyl derivatives

Synthetic approaches designed to provide 1H- and 2H-indazolyl derivatives of potential biological interest are reported. Special emphasis has been placed on the characterization of indazolylpyridinium products generated from reactions between indazole and 4-chloro-1-methylpyridinium iodide under various conditions. A stable mixture consisting of 3 parts of the 1H-isomer 9 to 1 part of the 2H-isomer 10 was obtained at room temperature in the presence of the base 2,2,6,6-tetramethylpiperidine (TMP). The same reaction at 60 °C gave only the 1H-isomer 9. At 100 °C in the absence of TMP only the 2H-isomer 10 was formed. The isomerization of 10 to 9 was found to proceed quantitatively at 60 °C but only in the presence of TMP. The effects of temperature and base on the course of these reactions are rationalized in terms of kinetic and thermodynamic parameters.